AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

GlycoMimetics Inc. (GLYC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.25

-0.01 (-3.29%)

At close: Jan 28, 2025, 2:32 PM

undefined% (undefined)

Bid	0.25
Market Cap	16.12M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.62
PE Ratio (ttm)	-0.4
Forward PE	n/a
Analyst	Hold

Ask	0.25
Volume	70,706
Avg. Volume (20D)	21,100,327
Open	0.26
Previous Close	0.26
Day's Range	0.25 - 0.26
52-Week Range	0.14 - 3.47
Beta	undefined

About GLYC

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing G...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 10, 2014

Employees 35

Stock Exchange NASDAQ

Ticker Symbol GLYC

Website https://www.glycomimetics.com

Analyst Forecast

According to 3 analyst ratings, the average rating for GLYC stock is "Hold." The 12-month stock price forecast is $12, which is an increase of 4700.00% from the latest price.

Buy 33.33%

Hold 66.67%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago

+191.32%

GlycoMimetics shares are trading higher after the ... Unlock content with Pro Subscription

7 months ago

+25.28%

GlycoMimetics shares are trading higher after the company disclosed that Chief Medical Officer Edwin Rock bought 305,000 shares at an average price of $0.26 per share.

News

2 months ago · businesswire.com

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics,...

3 months ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating GlycoMimetics (NASDAQ: GLYC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crescent. Click here to ...

3 months ago · businesswire.com

GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of GlycoMimetics, Inc. (NASDAQ: GLYC) and Crescent Biopharma, Inc. is fair to GlycoMimetic...

3 months ago · businesswire.com

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...